当前位置:首页 >财报库 > 报告详情

【美国精准皮肤病学创新疗法开发公司】Azitra, Inc.(AZTR)美股招股说明书 S-1(2025-07-18首版)(英文版)(37页).pdf

上传人: 白**** 编号:731228 2025-07-21 37页 1.20MB

下载:

1、S-1 1 forms-1.htm S-1 Registration No.333-UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933 AZITRA,INC.(Exact name of registrant as specified in its charter)Delaware 2834 46-4478536(State or other jurisdiction ofincorpor

2、ation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification Number)21 Business Park DriveBranford,CT 06405(203)646-6446(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Francisco D.Salva21 Bu

3、siness Park DriveBranford,CT 06405(203)646-6446(Name,address,including zip code,and telephone number,including area code,of agent for service)Copies to:Faith L.Charles,Esq.Todd Mason,Esq.Thompson Hine LLP300 Madison Avenue,27th FloorNew York,New York 10017-6232Tel:(212)344-6101 Approximate date of c

4、ommencement of proposed sale to the public:As soon as practicable after this Registration Statement becomes effective.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,check the followingbox

5、.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the following box and list the Securities Actregistration statement number of the earlier effective registration statement for the same offering.If this Form is a pos

6、t-effective amendment filed pursuant to Rule 462(c)under the Securities Act,check the following box and list the Securities Act registration statement number ofthe earlier effective registration statement for the same offering.If this Form is a post-effective amendment filed pursuant to Rule 462(d)u

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要概括如下: 1. Azitra公司是一家专注于开发创新疗法用于精准皮肤病学领域的临床阶段生物制药公司,拥有约1500种独特细菌菌株的微生物库。 2. 公司目前主要开发ATR-12、ATR-04和ATR-01三个产品,分别用于治疗Netherton综合征、EGFR抑制剂引起的皮疹和鱼鳞病。 3. 公司与Bayer和多家学术机构合作,利用其平台开发更多精准皮肤病学产品。 4. 公司拥有3项已授权的美国专利和12项待授权的美国专利申请,涵盖其业务发展的重要技术。 5. 本次发行涉及向投资者出售Azitra公司股票,公司不会获得任何发行收入。若投资者行权,公司可能获得120万美元的发行收入。 6. 公司计划将发行收入用于营运资金和一般公司用途。 7. 投资公司股票存在较高风险,投资者可能面临投资损失。
Azitra公司的核心产品是什么? Azitra公司的市场机会有多大? Azitra公司的竞争优势是什么?
客服
商务合作
小程序
服务号
折叠